Authors
1 UFUK UNİVERSİTY
2 BASKENT UNIVERSİTY
Abstract
Abstract
Background: Venous thromboembolism (VTE) increases patient's morbidity and mortality after orthopedic surgeries, and as such, prophylaxis is a routine practice after total joint replacement. Although there are many effective and safe prophylactic agents, clinical results are suboptimal. The aim of this study was to compare clinical and ultrasonographic results for the use of low molecule weight heparin (LMWH) and Rivaroxaban in patients undergoing total knee replacement.
Methods: In a prospective cross-sectional study 325 patients were enrolled in receiving Enoxaparin or Rivaroxaban as thromboprophylaxis in their total knee replacement surgery. They had pre and post-operative doppler ultrasonography for diagnosis of thromboembolism. They were followed for a minimum of two years. The status and occurrence of VTE was evaluated . Patients were compared in terms of gender, body mass index (BMI), smoking, diabetes mellitus (DM) and previous VTE history.
Results: The 325 eligible patients provided a sample of 130 (40%) male and 195 (60%) female. The average patient age (SD) was 63.2 (14.3).A total of 40 (12.3%) patients (27 on LMWH, and 13 on Rivaroxaban), had DVT at the lower extremity .15 (4.6 %) patients-11from LMWH and 4 from Rivaroxaban group had pulmonary embolism (PE). 5 patients (1.5%) -4 on LMWH, 1 on Rivaroxaban- had cerebrovascular thromboembolism. The incidence of thromboembolism was found to be similar in both prophylactic regimes. On the other hand, 2 patients (0.6%) had spontaneous retroperitoneal bleeding from LMWH group. The PE patients had history of DVT. DVT occurred in patients with risk factors of obesity, diabetes or smoking.
Conclusion: There was no difference between the use of rivaroxaban and enoxaparin for thromboembolic prophylaxis in total knee replacement in terms of occurrence of venous thrombosis and PE. Long-term thromboembolic prophylactic is preferred in cases with smoking, diabetes and obesity. Patients with previous venous thromboembolism are at a high risk for pulmonary and cerebrovascular embolism. Progressive hematocrit drop should alert the surgeon towards spontaneous retroperitoneal bleeding in the patients taking enoxaparin for thromboprophylaxis after total knee replacement surgery.
Keywords
- Brown TS, Huo MH. New anticoagulants for thromboprophylaxis after total knee arthroplasty. Am J Orthop 2013; 42: 424‐429.
- Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119: 132‐175.
- Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R, Kalodiki E, Myers K, Samama M, Sasahara A; Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20(3): 1‐37.
- Warwick D, Friedman RJ, Agnelli G, Gil‐Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799‐807.
- Selby R, Geerts WH. Venous thromboembolism: risk factors and prophylaxis. Semin Respir Crit Care Med 2000; 21: 493‐501.
- Beyer J, Schellong S. Deep vein thrombosis: Current diagnostic strategy. Eur J Intern Med 2005; 16: 238‐246.
- Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta‐analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging 2005; 3: 2‐13.
- Thomas SM, Goodacre SW, Sampson FC, Van Beek EJ. Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta‐ analysis. Clin Radiol 2008; 63: 299‐304.
- Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, Endorse investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross‐sectional study. Lancet 2008; 2: 387‐394.
- Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005; 87: 2097‐2112.
- Falck‐Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐ Based Clinical Practice Guidelines. Chest 2012; 141: 278‐ 325.
- Fassiadis N. Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis. Br J Hosp Med. 2011; 72: 486‐487.
- Chen T, Lam S. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev 2009; 17: 192‐197.
- Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2013; 95: 1801‐1811.
- Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg 2011; 19: 777‐778.
- Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost‐effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010; 104: 760‐770.
- Nieto JA, Espada NG, Merino, RG, Gonzalez TC. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool‐analysis of phase III randomized clinical trials. Thromb Res 2012; 130: 183‐191.
- Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673‐1680.
- Huang HF, Li SS, Yang XT, Xie Q, Tian XB. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta‐analysis. Medicine 2018; 97(48):1‐9.
- Shahcheraghi GH, Javid M, Arasteh MM. Thromboembolic disease after knee arthroplasty is rare in southern Iran. J Orthop 2014; 31(2):86‐91.
- Jameson SS, Rymaszewska M, Hui AC, James P, Serrano‐Pedraza I, Muller SD. Wound complications following rivaroxaban administration: a multicenter comparison with low‐molecular‐weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am 2012; 94‐A: 1554‐1558.
- Sachs RA, Smith JH, Kuney M, Paxton L. Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low‐dose warfarin after total knee arthroplasty. J Arthroplasty 2003: 18: 389‐395.
- Sunga KL, Bellolio MF, Gilmore RM, Cabrera D. Spontaneous retroperitoneal hematoma: etiology, characteristics, management, and outcome. J Emergency Med 2012; 43(2): e157–e161.
- Daliakopoulos SI, Bairaktaris A, Papadimitriou D, Pappas P. Gigantic retroperitoneal hematoma as a complication of anticoagulation therapy with heparin in therapeutic doses: a case report. J Med Case Rep. 2008, 2(1): 162. 10.1186/1752‐1947‐2‐162.
- Lu HY, Wei W, Chen QW, Meng QG, Hu GH, Yi XL, Bai XZ. A rare life‐threatening disease: Unilateral kidney compressed by huge chronic spontaneous retroperitoneal hemorrhage. Therapeutics Clin Risk Manag 2018: 14: 489–492.
- Dabney A and B. Bastani B. Enoxaparin‐ associated severe retroperitoneal bleeding and abdominal compartment syndrome: A report of two cases. Inten Care Med 2001; 27(12): 1954–1957.
- Kunutsor SK, Beswick AD, Whitehouse MR, Blom AW. Systematic review of risk prediction scores for venous thromboembolism following joint replacement. Thromb Res 2018; 168: 148‐155.
)